0001209191-14-028398.txt : 20140421
0001209191-14-028398.hdr.sgml : 20140421
20140421110235
ACCESSION NUMBER: 0001209191-14-028398
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20140417
FILED AS OF DATE: 20140421
DATE AS OF CHANGE: 20140421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: APPLIED GENETIC TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001273636
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 593553710
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 11801 RESEARCH DRIVE
STREET 2: SUITE D
CITY: ALACHUA
STATE: FL
ZIP: 32615
BUSINESS PHONE: 386-462-2204
MAIL ADDRESS:
STREET 1: 11801 RESEARCH DRIVE
STREET 2: SUITE D
CITY: ALACHUA
STATE: FL
ZIP: 32615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BULLOCK LAWRENCE E
CENTRAL INDEX KEY: 0001206868
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36370
FILM NUMBER: 14773049
MAIL ADDRESS:
STREET 1: C/O BIOMIMETIC THERAPEUTICS, INC.
STREET 2: 389 NICHOL MILL LANE
CITY: FRANKLIN
STATE: TN
ZIP: 37067
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-04-17
0
0001273636
APPLIED GENETIC TECHNOLOGIES CORP
AGTC
0001206868
BULLOCK LAWRENCE E
C/O APPLIED GENETIC TECHNOLOGIES CORPORA
ALACHUA
FL
32615
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
14.08
2014-04-17
4
A
0
2502
0.00
A
2024-04-17
Common Stock
2502
2502
D
Option becomes exercisable for 25% of the underlying shares on February 3, 2015, and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares on February 3, 2018.
/s/ Hemmie Chang, attorney-in-fact for Lawrence E. Bullock
2014-04-21
EX-24.4_518884
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby authorizes Hemmie Chang
and Robert W. Sweet, Jr., each of Foley Hoag LLP, to execute for and on behalf
of the undersigned, in the undersigned's capacity as a director of Applied
Genetic Technologies Corporation (the "Company"), a Form ID, Forms 3, 4 and 5,
and any amendments thereto, and cause such form(s) to be filed with the United
States Securities and Exchange Commission pursuant to Section 16(a) of the
Securities Act of 1934, relating to the undersigned's beneficial ownership of
securities in the Company. The undersigned hereby grants to the attorney-in-fact
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do personally present, with full power of
substitution, resubstitution or revocation, hereby ratifying and confirming all
that such attorney-in-fact, or such attorney's-in-fact substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorney-in-fact, in serving in such capacity at the request
of the undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 13th day of February, 2014.
/s/ Lawrence E. Bullock
Lawrence E. Bullock